MK-2206 (hydro<wbr>chloride)

MK-2206 (hydrochloride)

CAT N°: 11593
Price:

From 65.00 55.25

Three related forms of the kinase Akt (1, 2, 3, also known as protein kinase B isoforms PKB?, ?, ?) modulate cell proliferation, metabolism, and survival as well as angiogenesis.{15560,16917} MK-2206 is an orally active, allosteric Akt inhibitor that is equally potent toward purified human recombinant Akt1 and Akt2 (IC50s = 5 and 12 nM, respectively) and approximately 5-fold less potent against human Akt3 (IC50 = 65 nM).{24817} In combination with other anticancer agents including topoisomerase inhibitors, antimetabolites, antimicrotubule agents, DNA cross-linkers or growth factor inhibitors, MK-2206 has been shown to synergistically inhibit cell proliferation of human cancer cell lines.{24817} At 5 ?M, MK-2206 significantly enhances apoptosis in hematopoietic cells treated with chemotherapeutics.{24816}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, dihydrochloride
  • Correlated keywords
    • 1032349-93-1 kinases inhibitors Akt1 Akt2 Akt3 proteins B PKB? PKB? PKB? cells proliferation apoptosis anticancers anti-cancers anti cancers chemotherapy Akt-1 Akt-2 Akt-3 1 2 3 one two three Akts MKs 2206 MK-2206 HCl allosteric inhibits inhibitors hematopoietic chemotherapeutics signals transductions PKB.alpha. PKBa PKB.beta. PKBb PKB.gamma. PKBg metabolism survival angiogenesis humans
  • Product Overview:
    Three related forms of the kinase Akt (1, 2, 3, also known as protein kinase B isoforms PKB?, ?, ?) modulate cell proliferation, metabolism, and survival as well as angiogenesis.{15560,16917} MK-2206 is an orally active, allosteric Akt inhibitor that is equally potent toward purified human recombinant Akt1 and Akt2 (IC50s = 5 and 12 nM, respectively) and approximately 5-fold less potent against human Akt3 (IC50 = 65 nM).{24817} In combination with other anticancer agents including topoisomerase inhibitors, antimetabolites, antimicrotubule agents, DNA cross-linkers or growth factor inhibitors, MK-2206 has been shown to synergistically inhibit cell proliferation of human cancer cell lines.{24817} At 5 ?M, MK-2206 significantly enhances apoptosis in hematopoietic cells treated with chemotherapeutics.{24816}

We also advise you